NWAM LLC’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.37M Buy
37,307
+4,398
+13% +$368K 0.17% 131
2026
Q1
$2.64M Buy
32,909
+904
+3% +$74.5K 0.15% 140
2025
Q4
$2.7M Buy
32,005
+18,859
+143% +$1.55M 0.15% 139
2025
Q3
$992K Buy
13,146
+678
+5% +$53K 0.05% 278
2025
Q2
$988K Buy
12,468
+1,881
+18% +$140K 0.06% 270
2025
Q1
$767K Sell
10,587
-766
-7% -$54.8K 0.07% 245
2024
Q4
$840K Buy
11,353
+785
+7% +$54.9K 0.05% 289
2024
Q3
$697K Buy
+10,568
New +$768K 0.04% 318
2024
Q2
Sell
-10,580
Closed -$908K 272
2024
Q1
$908K Buy
10,580
+5
+0% +$420 0.07% 239
2023
Q4
$806K Sell
10,575
-61
-0.6% -$4.24K 0.06% 263
2023
Q3
$737K Sell
10,636
-143
-1% -$11.5K 0.07% 232
2023
Q2
$1.02M Sell
10,779
-416
-4% -$36.2K 0.08% 214
2023
Q1
$926K Buy
11,195
+15
+0.1% +$1.18K 0.09% 186
2022
Q4
$834K Sell
11,180
-62
-0.6% -$4.78K 0.07% 231
2022
Q3
$929K Buy
11,242
+293
+3% +$28.2K 0.09% 210
2022
Q2
$1.07M Sell
10,949
-4,059
-27% -$420K 0.1% 199
2022
Q1
$1.77M Buy
15,008
+10,790
+256% +$1.21M 0.14% 152
2021
Q4
$546K Buy
4,218
+1,079
+34% +$126K 0.04% 313
2021
Q3
$355K Buy
+3,139
New +$358K 0.03% 375

Other funds holding EW

NWAM LLC's EW Position: Q2 2026 in Review

NWAM LLC increased its Edwards Lifesciences (EW) stake by 13% in Q2 2026, buying an estimated $368K and bringing the position to 37,307 shares worth $3.37M. The position accounts for 0.17% of the portfolio, ranked #131.

NWAM LLC first reported a position in EW in Q3 2021 and has held it in 19 quarters since. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • NWAM LLC held 37,307 shares of Edwards Lifesciences worth $3.37M as of Q2 2026.
  • NWAM LLC bought 4,398 Edwards Lifesciences shares in Q2 2026, an estimated $368K.
  • Edwards Lifesciences made up 0.17% of NWAM LLC's portfolio in Q2 2026, its #131 holding.
  • NWAM LLC first reported a position in Edwards Lifesciences in Q3 2021 and has held it in 19 quarters since.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on NWAM LLC's 13F filing for Q2 2026, filed 23 Jul 2026.